Ewan R Pearson

List of Publications by Year
in descending order

137 papers	10,948 citations	61857 43 h-index	33814 99 g-index
148 all docs	148 docs citations	148 times ranked	13177 citing authors

#	Article	IF	Citations
1	The role of genetics in fetal programming of adult cardiometabolic disease. Journal of Developmental Origins of Health and Disease, 2022, 13, 292-299.	0.7	3
2	Prescribing Patterns and Response to Antihyperglycemic Agents Among Novel Clusters of Type 2 Diabetes in Asian Indians. Diabetes Technology and Therapeutics, 2022, 24, 190-200.	2.4	3
3	Four groups of type 2 diabetes contribute to the etiological and clinical heterogeneity in newly diagnosed individuals: An IMI DIRECT study. Cell Reports Medicine, 2022, 3, 100477.	3.3	39
4	The impact of birthweight on subsequent phenotype of type 2 diabetes in later life. Diabetic Medicine, 2022, 39, e14792.	1.2	4
5	Improvements in Awareness and Testing Have Led to a Threefold Increase Over 10 Years in the Identification of Monogenic Diabetes in the U.K.. Diabetes Care, 2022, 45, 642-649.	4.3	17
6	Prediction of Major Adverse Cardiovascular Events From Retinal, Clinical, and Genomic Data in Individuals With Type 2 Diabetes: A Population Cohort Study. Diabetes Care, 2022, 45, 710-716.	4.3	11
7	Young-onset diabetes in Asian Indians is associated with lower measured and genetically determined beta cell function. Diabetologia, 2022, 65, 973-983.	2.9	32
8	Response to Comment on Dawed et al. Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care 2021;44:2673â€“2682. Diabetes Care, 2022, 45, e82-e83.	4.3	0
9	Heterogeneity in phenotype, disease progression and drug response in type 2 diabetes. Nature Medicine, 2022, 28, 982-988.	15.2	48
10	Precision Medicine in Diabetes. Handbook of Experimental Pharmacology, 2022, , .	0.9	1
11	A roadmap to achieve pharmacological precision medicine in diabetes. Diabetologia, 2022, 65, 1830-1838.	2.9	16
12	A Polygenic Score for Type 2 Diabetes Risk Is Associated With Both the Acute and Sustained Response to Sulfonylureas. Diabetes, 2021, 70, 293-300.	0.3	22
13	Genome-Wide Association Analysis of Pancreatic Beta-Cell Glucose Sensitivity. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 80-90.	1.8	5
14	The Relationship between AKI and CKD in Patients with Type 2 Diabetes: An Observational Cohort Study. Journal of the American Society of Nephrology: JASN, 2021, 32, 138-150.	3.0	56
15	The Impact of Low-dose Gliclazide on the Incretin Effect and Indices of Beta-cell Function. Journal of Clinical Endocrinology and Metabolism, 2021, 106, 2036-2046.	1.8	9
16	Interaction between Omeprazole and Gliclazide in Relation to CYP2C19 Phenotype. Journal of Personalized Medicine, 2021, 11, 367.	1.1	6
17	Cohort profile: DOLORisk Dundee: a longitudinal study of chronic neuropathic pain. BMJ Open, 2021, 11, e042887.	0.8	7
18	Polymorphism in INSR Locus Modifies Risk of Atrial Fibrillation in Patients on Thyroid Hormone Replacement Therapy. Frontiers in Genetics, 2021, 12, 652878.	1.1	1

#	Article	IF	Citations
19	Replication and cross-validation of type 2 diabetes subtypes based on clinical variables: an IMI-RHAPSODY study. Diabetologia, 2021, 64, 1982-1989.	2.9	44
20	Utilizing Large Electronic Medical Record Data Sets to Identify Novel Drugâ€“Gene Interactions for Commonly Used Drugs. Clinical Pharmacology and Therapeutics, 2021, 110, 816-825.	2.3	5
21	Profiles of Glucose Metabolism in Different Prediabetes Phenotypes, Classified by Fasting Glycemia, 2-Hour OGTT, Glycated Hemoglobin, and 1-Hour OGTT: An IMI DIRECT Study. Diabetes, 2021, 70, 2092-2106.	0.3	17
22	Using machine learning approaches for multi-omics data analysis: A review. Biotechnology Advances, 2021, 49, 107739.	6.0	277
23	The genetic association of the transcription factor NPAT with glycemic response to metformin involves regulation of fuel selection. PLoS ONE, 2021, 16, e0253533.	1.1	0
24	Distinct Molecular Signatures of Clinical Clusters in People With Type 2 Diabetes: An IMI-RHAPSODY Study. Diabetes, 2021, 70, 2683-2693.	0.3	26
25	Evidence of a Causal Relationship between Serum Thyroid-Stimulating Hormone and Osteoporotic Bone Fractures. European Thyroid Journal, 2021, 10, 439-446.	1.2	5
26	Genomic editing of metformin efficacy-associated genetic variants in SLC47A1 does not alter SLC47A1 expression. Human Molecular Genetics, 2021, , .	1.4	2
27	Processes Underlying Glycemic Deterioration in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2021, 44, 511-518.	4.3	16
28	Genome-Wide Meta-analysis Identifies Genetic Variants Associated With Glycemic Response to Sulfonylureas. Diabetes Care, 2021, 44, 2673-2682.	4.3	23
29	Dorothy Hodgkin Lecture 2021: Drugs, genes and diabetes. Diabetic Medicine, 2021, 38, e14726.	1.2	9
30	Elevated circulating follistatin associates with an increased risk of type 2 diabetes. Nature Communications, 2021, 12, 6486.	5.8	31
31	Association of Genetic Variant at Chromosome 12q23.1 With Neuropathic Pain Susceptibility. JAMA Network Open, 2021, 4, e2136560.	2.8	16
32	Visit-to-Visit HbA1c Variability Is Associated With Cardiovascular Disease and Microvascular Complications in Patients With Newly Diagnosed Type 2 Diabetes. Diabetes Care, 2020, 43, 426-432.	4.3	85
33	Circulating Tissue Factor-Positive Procoagulant Microparticles in Patients with Type 1 Diabetes . Diabetes, Metabolic Syndrome and Obesity: Targets and Therapy, 2020, Volume 12, 2819-2828.	1.1	4
34	Metformin increases fasting glucose clearance and endogenous glucose production in non-diabetic individuals. Diabetologia, 2020, 63, 444-447.	2.9	22
35	Reducing Glut2 throughout the body does not result in cognitive behaviour differences in aged male mice. BMC Research Notes, 2020, 13, 438.	0.6	2
36	Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care, 2020, 43, 1948-1957.	4.3	45

#	Article	IF	Citations
37	Predicting post one-year durability of glucose-lowering monotherapies in patients with newly-diagnosed type 2 diabetes mellitus â€“ A MASTERMIND precision medicine approach (UKPDS 87). Diabetes Research and Clinical Practice, 2020, 166, 108333.	1.1	3
38	Monogenic Diabetes: From Genetic Insights to Population-Based Precision in Care. Reflections From a Diabetes Care Editorsâ€™ Expert Forum. Diabetes Care, 2020, 43, 3117-3128.	4.3	65
39	In a cohort of individuals with type 2 diabetes using the drug sulfasalazine, HbA 1c lowering is associated with haematological changes. Diabetic Medicine, 2020, 38, e14463.	1.2	1
40	Whole blood co-expression modules associate with metabolic traits and type 2 diabetes: an IMI-DIRECT study. Genome Medicine, 2020, 12, 109.	3.6	8
41	Response to Comment on Gan et al. Efficacy of Modern Diabetes Treatments DPP-4i, SGLT-2i, and GLP-1RA in White and Asian Patients With Diabetes: A Systematic Review and Meta-analysis of Randomized Controlled Trials. Diabetes Care 2020;43:1948â€“1957. Diabetes Care, 2020, 43, e202-e203.	4.3	0
42	Dietary metabolite profiling brings new insight into the relationship between nutrition and metabolic risk: An IMI DIRECT study. EBioMedicine, 2020, 58, 102932.	2.7	3
43	Obesity, clinical, and genetic predictors for glycemic progression in Chinese patients with type 2 diabetes: A cohort study using the Hong Kong Diabetes Register and Hong Kong Diabetes Biobank. PLoS Medicine, 2020, 17, e1003209.	3.9	31
44	Risk of Anemia With Metformin Use in Type 2 Diabetes: A MASTERMIND Study. Diabetes Care, 2020, 43, 2493-2499.	4.3	29
45	Novel subgroups of type 2 diabetes and their association with microvascular outcomes in an Asian Indian population: a data-driven cluster analysis: the INSPIRED study. BMJ Open Diabetes Research and Care, 2020, 8, e001506.	1.2	112
46	Genetic Risk of Diverticular Disease Predicts Early Stoppage of Nicorandil. Clinical Pharmacology and Therapeutics, 2020, 108, 1171-1175.	2.3	4
47	Precision medicine in diabetes: a Consensus Report from the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetologia, 2020, 63, 1671-1693.	2.9	102
48	Precision Medicine in Diabetes: A Consensus Report From the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD). Diabetes Care, 2020, 43, 1617-1635.	4.3	204
49	Predicting and elucidating the etiology of fatty liver disease: A machine learning modeling and validation study in the IMI DIRECT cohorts. PLoS Medicine, 2020, 17, e1003149.	3.9	47
50	Dapagliflozin Versus Placebo on Left Ventricular Remodeling in Patients With Diabetes and Heart Failure: The REFORM Trial. Diabetes Care, 2020, 43, 1356-1359.	4.3	102
51	The role of physical activity in metabolic homeostasis before and after the onset of type 2 diabetes: an IMI DIRECT study. Diabetologia, 2020, 63, 744-756.	2.9	12
52	Strategies to identify individuals with monogenic diabetes: results of an economic evaluation. BMJ Open, 2020, 10, e034716.	0.8	8
53	Risk factors for genital infections in people initiating SGLT2 inhibitors and their impact on discontinuation. BMJ Open Diabetes Research and Care, 2020, 8, e001238.	1.2	43
54	Post-load glucose subgroups and associated metabolic traits in individuals with type 2 diabetes: An IMI-DIRECT study. PLoS ONE, 2020, 15, e0242360.	1.1	7

#	Article	IF	Citations
55	Title is missing!. , 2020, 17, e1003149.		0
56	Title is missing!. , 2020, 17, e1003149.		0
57	Title is missing!. , 2020, 17, e1003149.		0
58	Title is missing!. , 2020, 17, e1003149.		0
59	Title is missing!. , 2020, 17, e1003149.		0
60	4th ESPT Conference: pharmacogenomics and personalized medicineÂâ€“ research progress and clinical implementation. Pharmacogenomics, 2019, 20, 1063-1069.	0.6	1
61	Motivations for data sharingâ€"views of research participants from four European countries: A DIRECT study. European Journal of Human Genetics, 2019, 27, 721-729.	1.4	30
62	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: descriptive characteristics of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 2019, 62, 1601-1615.	2.9	22
63	Genetic studies of abdominal MRI data identify genes regulating hepcidin as major determinants of liver iron concentration. Journal of Hepatology, 2019, 71, 594-602.	1.8	23
64	Type 2 diabetes: a multifaceted disease. Diabetologia, 2019, 62, 1107-1112.	2.9	129
65	Diabetes: Is There a Future for Pharmacogenomics Guided Treatment?. Clinical Pharmacology and Therapeutics, 2019, 106, 329-337.	2.3	29
66	Variation in the Plasma Membrane Monoamine Transporter (PMAT) (Encoded by SLC29A4) and Organic Cation Transporter 1 (OCT1) (Encoded by SLC22A1) and Gastrointestinal Intolerance to Metformin in Type 2 Diabetes: An IMI DIRECT Study. Diabetes Care, 2019, 42, 1027-1033.	4.3	43
67	Time trends in prescribing of type 2 diabetes drugs, glycaemic response and risk factors: A retrospective analysis of primary care data, 2010â€"2017. Diabetes, Obesity and Metabolism, 2019, 21, 1576-1584.	2.2	64
68	What to do with diabetes therapies when HbA1c lowering is inadequate: add, switch, or continue? A MASTERMIND study. BMC Medicine, 2019, 17, 79.	2.3	10
69	Development and validation of multivariable clinical diagnostic models to identify type 1 diabetes requiring rapid insulin therapy in adults aged 18â€"50 years. BMJ Open, 2019, 9, e031586.	0.8	49
70	Zinc Transporter 8 Autoantibodies (ZnT8A) and a Type 1 Diabetes Genetic Risk Score Can Exclude Individuals With Type 1 Diabetes From Inappropriate Genetic Testing for Monogenic Diabetes. Diabetes Care, 2019, 42, e16-e17.	4.3	19
71	Reflections on the sulphonylurea story: A drug class at risk of extinction or a drug class worth reviving?. Diabetes, Obesity and Metabolism, 2019, 21, 761-771.	2.2	11
72	Genome-Wide and Abdominal MRI Data Provide Evidence That a Genetically Determined Favorable Adiposity Phenotype Is Characterized by Lower Ectopic Liver Fat and Lower Risk of Type 2 Diabetes, Heart Disease, and Hypertension. Diabetes, 2019, 68, 207-219.	0.3	72

#	Article	IF	Citations
73	A Type 1 Diabetes Genetic Risk Score Can Identify Patients With GAD65 Autoantibodyâ€“Positive Type 2 Diabetes Who Rapidly Progress to Insulin Therapy. Diabetes Care, 2019, 42, 208-214.	4.3	35
74	Sharing data for future research'engaging participants' views about data governance beyond the original project: a DIRECT Study. Genetics in Medicine, 2019, 21, 1131-1138.	1.1	34
75	Pharmacogenetics and target identification in diabetes. Current Opinion in Genetics and Development, 2018, 50, 68-73.	1.5	8
76	Genetic Variants in CPA6 and PRPF31 Are Associated With Variation in Response to Metformin in Individuals With Type 2 Diabetes. Diabetes, 2018, 67, 1428-1440.	0.3	32
77	Formalising recall by genotype as an efficient approach to detailed phenotyping and causal inference. Nature Communications, 2018, 9, 711.	5.8	54
78	Precision Medicine in Type 2 Diabetes: Clinical Markers of Insulin Resistance Are Associated With Altered Short- and Long-term Glycemic Response to DPP-4 Inhibitor Therapy. Diabetes Care, 2018, 41, 705-712.	4.3	67
79	Rates of glycaemic deterioration in a real-world population with type 2 diabetes. Diabetologia, 2018, 61, 607-615.	2.9	40
80	Quantitative MRI evaluation of whole abdomen adipose tissue volumes in healthy volunteersâ€”validation of technique and implications for clinical studies. British Journal of Radiology, 2018, 91, 20180025.	1.0	6
81	Interaction between variants in the CYP2C9 and POR genes and the risk of sulfonylureaâ€induced hypoglycaemia: A GoDARTS S tudy. Diabetes, Obesity and Metabolism, 2018, 20, 211-214.	2.2	24
82	Metabolite ratios as potential biomarkers for type 2 diabetes: a DIRECT study. Diabetologia, 2018, 61, 117-129.	2.9	32
83	Evaluating associations between the benefits and risks of drug therapy in type 2 diabetes: a joint modeling approach. Clinical Epidemiology, 2018, Volume 10, 1869-1877.	1.5	14
84	The governance structure for data access in the DIRECT consortium: an innovative medicines initiative (IMI) project. Life Sciences, Society and Policy, 2018, 14, 20.	3.1	7
85	A UK nationwide prospective study of treatment change in MODY: genetic subtype and clinical characteristics predict optimal glycaemic control after discontinuing insulin and metformin. Diabetologia, 2018, 61, 2520-2527.	2.9	65
86	Sex and BMI Alter the Benefits and Risks of Sulfonylureas and Thiazolidinediones in Type 2 Diabetes: A Framework for Evaluating Stratification Using Routine Clinical and Individual Trial Data. Diabetes Care, 2018, 41, 1844-1853.	4.3	91
87	Performance of Cardiovascular Disease Risk Scores in People Diagnosed With Type 2 Diabetes: External Validation Using Data From the National Scottish Diabetes Register. Diabetes Care, 2018, 41, 2010-2018.	4.3	47
88	Cohort Profile: Genetics of Diabetes Audit and Research in Tayside Scotland (GoDARTS). International Journal of Epidemiology, 2018, 47, 380-381j.	0.9	59
89	Effectiveness and safety of long-term treatment with sulfonylureas in patients with neonatal diabetes due to KCNJ11 mutations: an international cohort study. Lancet Diabetes and Endocrinology,the, 2018, 6, 637-646.	5.5	120
90	C-Peptide Decline in Type 1 Diabetes Has Two Phases: An Initial Exponential Fall and a Subsequent Stable Phase. Diabetes Care, 2018, 41, 1486-1492.	4.3	81

#	Article	IF	Citations
91	The search for predictive metabolic biomarkers for incident T2DM. Nature Reviews Endocrinology, 2018, 14, 444-446.	4.3	3
92	Integrative network analysis highlights biological processes underlying GLP-1 stimulated insulin secretion: A DIRECT study. PLoS ONE, 2018, 13, e0189886.	1.1	9
93	Quantifying the extent to which index event biases influence large genetic association studies. Human Molecular Genetics, 2017, 26, ddw433.	1.4	40
94	Acute kidney injury, plasma lactate concentrations and lactic acidosis in metformin users: <scp>A GoDarts</scp> study. Diabetes, Obesity and Metabolism, 2017, 19, 1579-1586.	2.2	49
95	A Genome-Wide Association Study of IVGTT-Based Measures of First-Phase Insulin Secretion Refines the Underlying Physiology of Type 2 Diabetes Variants. Diabetes, 2017, 66, 2296-2309.	0.3	102
96	Evidence-based prioritisation and enrichment of genes interacting with metformin in type 2 diabetes. Diabetologia, 2017, 60, 2231-2239.	2.9	4
97	Costs and Treatment Pathways for Type 2 Diabetes in the UK: A Mastermind Cohort Study. Diabetes Therapy, 2017, 8, 1031-1045.	1.2	9
98	The mechanisms of action of metformin. Diabetologia, 2017, 60, 1577-1585.	2.9	1,421
99	CKMGlu83Gly Is Associated With Blunted Creatine Kinase Variation, but Not With Myalgia. Circulation: Cardiovascular Genetics, 2017, 10, .	5.1	5
100	Population-Based Assessment of a Biomarker-Based Screening Pathway to Aid Diagnosis of Monogenic Diabetes in Young-Onset Patients. Diabetes Care, 2017, 40, 1017-1025.	4.3	111
101	Sustained influence of metformin therapy on circulating glucagonâ€like peptideâ€1 levels in individuals with and without type 2 diabetes. Diabetes, Obesity and Metabolism, 2017, 19, 356-363.	2.2	47
102	Defining drug response for stratified medicine. Drug Discovery Today, 2017, 22, 173-179.	3.2	24
103	A common missense variant of LILRB5 is associated with statin intolerance and myalgia. European Heart Journal, 2017, 38, 3569-3575.	1.0	41
104	Predicting glycated hemoglobin levels in the non-diabetic general population: Development and validation of the DIRECT-DETECT prediction model - a DIRECT study. PLoS ONE, 2017, 12, e0171816.	1.1	13
105	Adherence to Oral Glucose-Lowering Therapies and Associations With 1-Year HbA1c: A Retrospective Cohort Analysis in a Large Primary Care Database. Diabetes Care, 2016, 39, 258-263.	4.3	79
106	Crossover studies can help the individualisation of care in type 2 diabetes: the MASTERMIND approach. Practical Diabetes, 2016, 33, 115-117.	0.1	0
107	Research into the effect Of SGLT2 inhibition on left ventricular remodelling in patients with heart failure and diabetes mellitus (REFORM) trial rationale and design. Cardiovascular Diabetology, 2016, 15, 97.	2.7	49
108	Pharmacogenomics in diabetes mellitus: insights into drug action and drug discovery. Nature Reviews Endocrinology, 2016, 12, 337-346.	4.3	47

#	Article	IF	Citations
109	Genetic Evidence for a Link Between Favorable Adiposity and Lower Risk of Type 2 Diabetes, Hypertension, and Heart Disease. Diabetes, 2016, 65, 2448-2460.	0.3	122
110	Effect of Serotonin Transporter 5-HTTLPR Polymorphism on Gastrointestinal Intolerance to Metformin: A GoDARTS Study. Diabetes Care, 2016, 39, 1896-1901.	4.3	41
111	Variation in the glucose transporter gene SLC2A2 is associated with glycemic response to metformin. Nature Genetics, 2016, 48, 1055-1059.	9.4	165
112	Statistical power considerations in genotype-based recall randomized controlled trials. Scientific Reports, 2016, 6, 37307.	1.6	10
113	CYP2C8 and SLCO1B1 Variants and Therapeutic Response to Thiazolidinediones in Patients With Type 2 Diabetes. Diabetes Care, 2016, 39, 1902-1908.	4.3	52
114	Systematic Population Screening, Using Biomarkers and Genetic Testing, Identifies 2.5% of the U.K. Pediatric Diabetes Population With Monogenic Diabetes. Diabetes Care, 2016, 39, 1879-1888.	4.3	172
115	Metformin and the gastrointestinal tract. Diabetologia, 2016, 59, 426-435.	2.9	472
116	Should Studies of Diabetes Treatment Stratification Correct for Baseline HbA1c?. PLoS ONE, 2016, 11, e0152428.	1.1	26
117	Dissecting the Etiology of Type 2 Diabetes in the Pima Indian Population. Diabetes, 2015, 64, 3993-3995.	0.3	7
118	Most People With Long-Duration Type 1 Diabetes in a Large Population-Based Study Are Insulin Microsecretors. Diabetes Care, 2015, 38, 323-328.	4.3	104
119	Association of Organic Cation Transporter 1 With Intolerance to Metformin in Type 2 Diabetes: A GoDARTS Study. Diabetes, 2015, 64, 1786-1793.	0.3	188
120	Clinical and Genetic Determinants of Progression of Type 2 Diabetes: A DIRECT Study. Diabetes Care, 2014, 37, 718-724.	4.3	59
121	Heritability of variation in glycaemic response to metformin: a genome-wide complex trait analysis. Lancet Diabetes and Endocrinology,the, 2014, 2, 481-487.	5.5	101
122	Discovery of biomarkers for glycaemic deterioration before and after the onset of type 2 diabetes: rationale and design of the epidemiological studies within the IMI DIRECT Consortium. Diabetologia, 2014, 57, 1132-1142.	2.9	48
123	Zinc transport and diabetes risk. Nature Genetics, 2014, 46, 323-324.	9.4	18
124	PS7 - 3. Predicting Glycated Haemoglobin in the Non-Diabetic General Population: a DIRECT Study. Nederlands Tijdschrift Voor Diabetologie, 2013, 11, 154-154.	0.0	0
125	New loci associated with birth weight identify genetic links between intrauterine growth and adult height and metabolism. Nature Genetics, 2013, 45, 76-82.	9.4	293
126	Common variants near ATM are associated with glycemic response to metformin in type 2 diabetes. Nature Genetics, 2011, 43, 117-120.	9.4	390

#	Article	IF	Citations
127	Reduced-Function SLC22A1 Polymorphisms Encoding Organic Cation Transporter 1 and Glycemic Response to Metformin: A GoDARTS Study. Diabetes, 2009, 58, 1434-1439.	0.3	153
128	Pharmacogenetics and future strategies in treating hyperglycaemia in diabetes. Frontiers in Bioscience - Landmark, 2009, Volume, 4348.	3.0	16
129	No differences in mortality between users of pancreatic-specific and non-pancreatic-specific sulphonylureas: a cohort analysis. Diabetes, Obesity and Metabolism, 2008, 10, 350-352.	2.2	20
130	Variation in TCF7L2 Influences Therapeutic Response to Sulfonylureas. Diabetes, 2007, 56, 2178-2182.	0.3	284
131	Macrosomia and Hyperinsulinaemic Hypoglycaemia in Patients with Heterozygous Mutations in the HNF4A Gene. PLoS Medicine, 2007, 4, e118.	3.9	349
132	Switching from Insulin to Oral Sulfonylureas in Patients with Diabetes Due to Kir6.2 Mutations. New England Journal of Medicine, 2006, 355, 467-477.	13.9	878
133	Relapsing diabetes can result from moderately activating mutations in KCNJ11. Human Molecular Genetics, 2005, 14, 925-934.	1.4	184
134	Contrasting Diabetes Phenotypes Associated With Hepatocyte Nuclear Factor-1Â and -1Â Mutations. Diabetes Care, 2004, 27, 1102-1107.	4.3	114
135	Activating Mutations in the Gene Encoding the ATP-Sensitive Potassium-Channel Subunit Kir6.2 and Permanent Neonatal Diabetes. New England Journal of Medicine, 2004, 350, 1838-1849.	13.9	1,077
136	Genetic cause of hyperglycaemia and response to treatment in diabetes. Lancet, The, 2003, 362, 1275-1281.	6.3	526
137	Genome-Wide Meta-Analysis Identifies the Organic Anion-Transporting Polypeptide Gene <i>SLCO1B1</i> and Statins as Modifiers of Glycemic Response to Sulfonylureas. SSRN Electronic Journal, 0, , .	0.4	0